Compare Pfizer Inc (PFE) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs UnitedHealth Group Inc — how do they compare? Pfizer Inc trades at $28.24 (market cap $158.56B), while UnitedHealth Group Inc trades at $379.61 (market cap $332.96B). The key difference: UnitedHealth Group Inc is far larger — about 2.1× Pfizer Inc's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and UnitedHealth Group Inc for 97 Days on average.
| PFE | UNH | |
|---|---|---|
Market Cap | $158.56B | $332.96B |
Volume | 44,138,282 | 7,273,749 |
Sector | Health | Health |
52-Week High | $29.02 | $436.35 |
52-Week Low | $23.67 | $259.02 |
Typical Hold Time | 158 Days | 97 Days |
Enterprise Value | $210.06B | $374.82B |
Dividend Yield | 6.18% | 2.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
UnitedHealth Group (UNH) trades at $375.98, showing minor daily weakness but maintaining a bullish technical signal. The company reported strong Q2 2026 earnings, beating estimates, and reaffirmed its full-year outlook. Revenue growth remains robust, though net margins have compressed from prior years. Analyst sentiment is overwhelmingly positive, with a consensus price target of $473.89 implying significant upside.
The outlook for UNH is favorable, driven by earnings momentum and strategic initiatives like AI investment. Key risks include regulatory pressures and medical cost trends. The stock presents a compelling opportunity for investors seeking exposure to a leading healthcare company with solid fundamentals and Wall Street support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
